Premium
5‐Hydroxytryptamine and Atrial Fibrillation:
Author(s) -
YUSUF SHAMIL,
AlSAADY NAAB,
CAMM A. JOHN
Publication year - 2003
Publication title -
journal of cardiovascular electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.193
H-Index - 138
eISSN - 1540-8167
pISSN - 1045-3873
DOI - 10.1046/j.1540-8167.2003.02381.x
Subject(s) - medicine , atrial fibrillation , cardiology , management of atrial fibrillation , valvular heart disease , disease , intensive care medicine
Serotonin and Atrial Fibrillation. 5‐Hydroxytryptamine, a recent addition to the list of hormonal triggers for atrial fibrillation (AF), may play a pivotal role in the induction of AF related not only to cardiac surgery but also to acute coronary syndromes, valvular heart disease, cardiomyopathies, alcoholism, aging, and conducting tissue disease. This review examines the supporting laboratory and clinical evidence and provides a comprehensive insight into the basic underlying mechanisms involved. It also delves into the potential benefits and limitations of 5‐HT 4 antagonists in the prevention and management of this arrhythmia. (J Cardiovasc Electrophysiol, Vol. 14, pp. 209‐214, February 2003)